Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced

See also
Status	Clinical Trial	Phase
Completed	`NCT01218555` - Study of Everolimus (RAD001) in Combination With Lenalidomide	Phase 1
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase 2
Withdrawn	`NCT04614766` - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05556473` - F-Tryptophan PET/CT in Human Cancers	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT02815969` - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02174549` - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer	Phase 1/Phase 2
Completed	`NCT02132468` - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers	Phase 2
Completed	`NCT02134639` - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation	N/A
Recruiting	`NCT01201096` - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	N/A
Terminated	`NCT01163526` - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies	N/A
Completed	`NCT01099228` - Combination Targeted Radiotherapy in Neuroendocrine Tumors	N/A
Completed	`NCT00171873` - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut	Phase 3
Active, not recruiting	`NCT05077384` - Open-label Study of Surufatinib in Japanese Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04544098` - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver	Early Phase 1
Active, not recruiting	`NCT02736500` - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2

NCT number	NCT01364415
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 1
Start date	August 2011
Completion date	April 2016

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms